- Home
- / NewGLAB Pharma
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
NewGLAB Pharma financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
₩6.9 K
2024-10-29
Market Capitalization
₩64.7 B
2024-07-19
Revenue
₩12.6 B
FY, 2023
CreditSafe Score
?
Score changed on Jun 09, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| KRW | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 |
|---|---|---|---|---|---|---|
| Revenue | 18.6B | 95.8B | 54.4B | 29.4B | 21.7B | 12.6B |
| Cost of goods sold | 17.1B | 68.2B | 44.8B | 23.8B | 16.2B | 11.5B |
| Gross profit | 1.6B | 27.7B | 9.7B | 5.8B | 20.8B | 1.2B |
| Gross profit margin, % | 29.0% | 17.9% | 19.8% | 95.9% | 9.6% | |
| Operating expense total | 6.1B | 27.1B | 24.2B | 29.0B | 31.1B | 13.9B |
| Depreciation and amortization | 1.4B | 735.3M | 3.6B | 12.6B | 24.2B | 987.0M |
| EBITDA | (4.5B) | (1.0B) | (14.9B) | (23.2B) | (10.3B) | (12.6B) |
| EBITDA margin, % | -1.1% | -27.4% | -79.0% | -47.2% | -100.0% | |
| EBIT | (6.5B) | (1.6B) | (18.8B) | (54.7B) | (67.3B) | 3.0B |
| EBIT margin, % | -1.6% | -34.6% | -186.4% | -309.9% | 23.8% | |
| Interest income | 556.1M | 605.0M | 655.7M | 851.6M | 392.1M | 254.3M |
| Interest expense | 1.6B | 2.3B | 4.0B | 4.0B | 4.0B | 4.0B |
| Pre tax profit | (7.8B) | (2.7B) | (23.4B) | (53.9B) | (74.4B) | (29.3M) |
| Income tax expense | (400.6M) | (51.0M) | (835.6M) | (2.0B) | (2.4B) | (933.3M) |
| Net Income | (7.4B) | (2.7B) | (22.6B) | (51.9B) | (72.0B) | 903.9M |